Trial Profile

HEC73543 Versus Salvage Chemotherapy in Relapsed or Refractory FLT3-ITD Acute Myeloid Leukemia: a Multicenter, Open-label, Randomized Phase 3 Trial

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 25 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Clifutinib besylate (Primary) ; Azacitidine; Azacitidine; Cytarabine; Cytarabine; Decitabine; Granulocyte colony-stimulating factors; Granulocyte colony-stimulating factors; Idarubicin; Idarubicin
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Registrational; Therapeutic Use
Sponsors Sunshine Lake Pharma

Most Recent Events

28 Apr 2026 Planned End Date changed from 14 Jun 2027 to 30 May 2028.
28 Apr 2026 Planned primary completion date changed from 10 Mar 2026 to 30 Nov 2027.
09 Apr 2025 Planned End Date changed from 14 May 2026 to 14 Jun 2027.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com